The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


EMA committee recommends full approval of Imbruvica to treat two blood cancers.....           European CHMP adopts positive opinion for Gilead?s Zydelig to treat chronic lymphocytic leukemia and follicular lymphoma.....           Novogen and CanTx appoint contract manufacturers to produce clinical batches of Cantrixil.....           TransCelerate selects Cognizant to develop a clinical trials collaboration platform.....           MYOS extends manufacturing, supply agreement for Fortetropin.....           biOasis releases quantitative results: siRNA-Transcendpep reduces target gene expression in the brain.....           GSK's over-the-counter spray Flonase gets FDA approval.....           Perrigo gets AB therapeutic equivalent rating from FDA for testosterone gel 1.0%.....           MacroGenics' IND for colorectal cancer drug candidate MGD007 gets FDA approval.....           Prometic Biosciences enters into new product development program.....           Merck enrols first patient in Phase III trial of letermovir for prevention of CMV infection.....           Still reeling from China bribery probe, GSK faces corruption scandal in Syria.....           With Shire deal in the bag, Humira leap helps AbbVie hold its own.....           Gilead's Zydelig, J&J's Imbruvica will go toe-to-toe in EU with nod for CLL.....           J&J builds 9-month supply of Doxil with creative problem solving.....           Bayer's Nexavar misses another study endpoint, this time for breast cancer.....           As legislator rails on potential Valeant-Allergan deal, Wall Street lines up to fund it.....           Merck whacks 600 sales reps as part of 8,500 bloodletting.....           GlaxoSmithKline files regulatory application in Europe for malaria vaccine.....           National Institute of Allergy and Infectious Diseases awards SRI International Contract to study new therapies for HIV and AIDS.....           Kinex announces allowance of IND application for KX2-391 ointment by USFDA.....           Onco360 named to Zydelig limited distribution network.....           WIRB-Copernicus acqures Alliance Biosciences.....           Abbott introduces new Similac breastfeeding supplement with DHA, Lutein and vitamin E.....           MYOS gets notice of allowance of US Patent Application for manufacturing methods of Fortetropin.....           Lightlake Therapeutics files IND application for Naloxone opioid overdose nasal spray.....           Biogen Idec's multiple sclerosis drug Plegridy gets European approval.....           Neurotrope, Mount Sinai to develop Bryostatin-1 for NPC treatment.....           BioSyent signs licensing deal for new urgent care drug product.....           FDA approves Eagle's malignant hyperthermia treatment Ryanodex.....           Eli Lilly's Q2 profit sags on patent expirations but beats (low) expectations.....           Can Gilead break into cancer? With Zydelig approval, it gets its chance.....           BMJ targets Pradaxa safety, scolding Boehringer, FDA and EMA alike.....           Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla.....           Bristol-Myers beats profit estimates, thanks to strong Yervoy, Eliquis numbers.....           Bristol-Myers enters into immuno-oncology collaboration with Ono Pharmaceutical.....           ArmaGen, Shire to develop AGT-182 for treatment of hunter syndrome.....           Mezzion Pharma begins clinical development program to evaluate Udenafil in adolescents with single ventricle heart defects.....           Sinovac receives Beijing CDC tender to supply seasonal flu vaccine Anflu.....           Essentialis gets foundation for Prader-Willi Research Grant to help advance DCCR for Prader-Willi syndrome.....           Biosceptre reports positive Phase I results for BIL-010t to treat Basal Cell Carcinoma.....           Welichem enters into termination agreement with Celestial and BWTP.....           Galena Biopharma inks licensing deal with MonoSol Rx for US rights of Zuplenz.....           Iroko Pharmaceuticals, CALOX partner to commercialize Zorvolex in Latin America.....           Antares starts dosing in Phase III QuickShot trial evaluating testosterone-deficient adult males.....           Puma Biotechnology revises Neratinib licensing deal with Pfizer.....           Judge refuses to toss off-label Revlimid marketing lawsuit against Celgene.....           GSK slimming further as sales fall on Advair competition.....           Biogen hikes its forecast as zippy Tecfidera fuels big profits.....           Pricey hep C drugs plus thrifty payers equal thorny consequences for patients.....           Pfizer looks to boost Harmonet contraceptive in Asia via loverly brand site.....           $9.9M 'golden hello' awaits Shire chief Ornskov at new AbbVie post.....           Payer pushback aside, Sovaldi, and so Gilead, has another huge quarter.....           Boehringer, University of Toronto form alliance for new therapeutic concepts in ubiquitin biology.....           Taiho Pharmaceutical invests $30m in Remiges BioPharma Fund.....           Galmed gets FDA clearance of IND of Armachol to treat fatty liver disorders.....           OPKO granted patent from US Patent & Trademark Office for RAYALDEE.....           Alnylam gets notice of allowance from USPTO for new patent broadly covering conjugate-based delivery of RNA Therapeutics.....           Tute Genomics biomarker discovery platform to support BYU's Alzheimer's disease genetics research.....           FDA grants Genentech?s Avastin priority review for recurrent platinum-resistant ovarian cancer.....           Regulus gets FDA orphan drug status for RG-012 to treat Alport Syndrome.....           Arena subsidiary inks marketing, supply deal with Abic for BELVIQ in Israel.....           Anavex receives cGMP manufacturing for drug candidate trial supplies.....           Advanced BioScience Laboratories acquires majority stake in Platine.....           Dipexium enrols first patient in Phase III trials of Locilex.....           Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter.....           Valeant-style cost cuts create win-win for Allergan shareholders, analysts say.....           Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data.....           News flash for biopharma bosses: More than half your employees want to leave.....           Cost-conscious payers are eyeing higher prices on diabetes drugs.....           Avastin nabs second-in-a-row priority review, this time in ovarian cancer.....           FDA approves Avanir's Phase II trial of MDD candidate AVP-786.....           CTI BioPharma expands access to PIXUVRI with approval in Israel.....           Celsion gets $1m NIH grant for Glioblastoma Research with ThermoDox and HIFU.....           Celladon announces In-license of stem cell factor development program.....           TFS selects OmniComm TrialMaster for global clinical trial research.....           Harvard Medical School, Phelan-McDermid Syndrome Foundation Contract leverages the tranSMART open-source knowledge management platform.....           Anacor Pharmaceuticals, Sandoz ink deal to commercialize KERYDIN in US.....           Durata Therapeutics launches DALVANCE for injection in US.....           Lannett inks deal with Symplmed for US distribution of authorized generic of ACEON.....           Regeneron, Bayer release positive Phase III trial results of EYLEA to treat DME.....           Synergy closes patient enrollment in Phase II trial of SP-333 in patients OIC.....           Animal health companies not exempt from FDA marketing regs, either.....           Roche CEO: No appetite for expensive megadeals here.....           Pharma peer pressure makes tax-friendly M&A targets the new must-have.....           Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant.....           Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong.....           JAMA: Hep C drugs could add $300 to every American's insurance premium.....           Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014.....           Amgen reports positive Phase III results for AMG 416 to treat secondary hyperparathyroidism in CKD patients.....           Agile Therapeutics announces allowance of additional patent claims for Skinfusion.....           Cynapsus Therapeutics commences Phase II clinical trials in US.....           Purdue Pharma gets FDA approval for 7.5 mcg/hour dosage strength of Butrans transdermal system CIII.....           MorphoSys gets additional patents on Ylanthia in US and first patent in China.....           Rexahn provides update on Phase I Supinoxin trial in cancer patients with solid tumors.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
APS Blog - Brendan Gilmore 'Is the tide really turning on antibiotic research stagnation?'
WEDNESDAY, 9 JULY 2014
. Last week, British Prime Minister David Cameron announced the launch of a Commission on Antimicrobial Resistance, the first global leader to declare the need for immediate global action to halt the rise of antibiotic resistance, promote public engagement, education and stewardship to arrest the global over-use of antibiotics and examine the economic and market barriers to global antibiotic research and development which have seen the last three decades of the ‘antibiotic era’ characterized by a dearth of research into new chemical diversity in the antibiotic arsenal, as major Big Pharma players exited the field and no new classes of antibiotics marketed for a quarter of a century. The Commission will be chaired by the world-renowned economist, Dr Jim O’Neill (former Chief Economist at Goldman Sachs and creator of the BRIC acronym to represent the four major developing economies Brazil, Russia, India and China which symbolize the decentralization of global economic power away from the G7 countries). The commission, hosted and funded by the Wellcome Trust, will produce a major international review, examining the broader issues of incentivizing the antibiotic drug pipeline, the economic issues surrounding antimicrobial resistance and improved use and stewardship of our existing antimicrobial agents. Quoting from the Wellcome Trust, the commission is tasked with examining the following themes:. the development, use and regulatory environment of antimicrobials, especially antibiotics, and explore how to make investments in new antibiotics more attractive to pharmaceutical companies and other funding bodies. the balance between effective and sustainable incentives for investment, and the need to conserve antimicrobial drugs so they can remain effective for as long as possible how governments and other funders can stimulate investment in new antimicrobials, and timeframes and mechanisms for implementation. increasing international cooperation and support for action by the international community, including much closer working with low- and middle-income countries on the issue”. Although the announcement has received a widespread welcome in the UK and beyond, the Prime Minister has received some criticism for appointing an economist (rather than a scientist, presumably) to chair the commission. However, the acknowledgement that the stagnation of antibiotic innovation on a scale which is failing to meet the demands of global antibiotic use in the face of mushrooming antibiotic resistance is primarily due to economic barriers is a critical one. Furthermore, as developing economies flourish, the rise in demand for antibiotics soars, supporting fledgling healthcare systems, agriculture-based economies and ageing populations. A commission chair with expert knowledge of BRIC and other emerging economies, themselves major global consumers of antibiotics and key targets for public educational and antimicrobial stewardship programmes, may yet prove a significant move. The commission commences its activities in the autumn, initially for a period of one year.. This establishment of the commission comes hot on the heels of the announcement that antibiotics, has been chosen as the challenge theme (as voted for by the British public) for the £10m Longitude Prize 2014. The challenge set for the Longitude Prize is to develop a cost-effective, accurate, rapid and easy-to-use test for bacterial infections to enable healthcare professionals across the globe to select and administer the right antibiotic for a particular infection, at the right time. Such point-of-care diagnostics will form the basis of strategies to curb the inappropriate use of antibiotic agents, protecting the limited arsenal of antimicrobial agents available against emerging antibiotic resistance. The challenge is open, as in the spirit of the original prize, to both amateur scientists and the professional scientific community to put forward ideas on how to solve it. The Longitude Prize, a £20,000 (today c. £2m) challenge established by an Act of Parliament, to find a practical solution that could find longitude accurate to half a degree (equivalent to 2 minutes), was awarded 300 years ago to John Harrison for his invention of the marine chronometer. John Harrison was a joiner and clockmaker with little formal education, whose invention allowed accurate global positioning and ensured Britain’s position as a naval super power. In parallel, John Hadley and Tobias Mayer perfected the apparatus and astronomical tables, which allowed longitudinal measurements via the lunar distance method. It can only be hoped that the prize will again give rise to more than one approach to solve the intractable problem of antimicrobial resistance. The Longitude Committee, led by Astronomer Royal Lord Martin Rees, are now finalizing the criteria for award of the £10 million prize, with proposals accepted from this autumn.. In May 2014, the Biotechnology and Biological Sciences Research Council (BBSRC) announced that combating antimicrobial resistance would become a key strategic priority, in line with the UK Department of Health Five Year Antimicrobial Resistance Strategy (2013-2018), calling for improved knowledge and understanding of antimicrobial resistance, conservation and stewardship of the efficacy of existing treatments and stimulation of the development of new antibiotics (and their alternatives), diagnostics and novel therapies. Also, in May 2014, the Royal Pharmaceutical Society’s Pharmaceutical Sciences Expert Advisory Panel (PS-EAP) published ‘New medicines, Better Medicines, Better Use of Medicines – A Guide to the Science Underpinning Pharmaceutical Practice’, highlighting the major challenges and opportunities faced when creating new medicines, improving existing medicines or ensuring better, safer use of medicines. In addition, the document makes seven recommendations for action arising from the challenges highlighted. Recommendation two of the guide is “stimulating new antimicrobial development and improving antimicrobial stewardship”.. So, clearly the political, societal and scientific will is behind the development of new antimicrobial drugs, education and stewardship for protection of those we have available and development of new therapies for infectious diseases. The crisis of antimicrobial resistance, leads to significant opportunities for the UK science and technology sector in leading the world in new antimicrobial agents and therapies and technologies aimed at point-of-care diagnosis of infection to facilitate appropriate, judicious use of antibiotics and other antimicrobial agents.. The APS microbiology and anti-infectives focus group seeks to be at the forefront of underpinning the importance of microbiology in the pharmaceutical sciences, public engagement on antimicrobial stewardship and providing a forum for the scientific discussion of cutting edge antimicrobials research and development in these exciting times for antimicrobial chemotherapy..
Contribute to a Round Table discussion on the development of a Manufacturing Classification System with speaker and contributors from Astra Zeneca, BMS and GSK.
FRIDAY, 4 JULY 2014
. On Tuesday 9th September 2014; 16:20 to 17:50 at the APS Pharm Sci Conference 2014. Speaker: Gavin Reynolds (AZ). Co-chairs: Michael Leane (BMS), Kendal Pitt (GSK).. This roundtable session will introduce the concept of a drug product Manufacturing Classification System (MCS) based on processing route and seeks feedback from the wider pharmaceutical science community on the best way to apply it to practice. The MCS is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on “ideal” ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. The four classes proposed are:. Class I: Direct Compression Class II: Dry Granulation Class III: Wet Granulation Class IV: Other Technologies. Input from interested parties is needed to develop this concept. In particular, feedback is sought on what API properties are important when selecting or modifying materials to enable an efficient pharmaceutical manufacturing process.
Join the APS Pharm Sci Conference debate
WEDNESDAY, 2 JULY 2014
Monday 8th September 7.00pm onwards. The APS Pharm Sci Conference is great for networking and this year there are more opportunities than ever. For example why not join the debate on Monday 8th September at 7.00pm in the De Havilland Club on the University campus? While getting your thoughts together on the topic ‘The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?’ you can enjoy a light buffet and liquid refreshments (which may or may not help the thought process!) for just £10!. The event is sponsored by the University of Hertfordshire and the Stevenage Bioscience Catalyst and provides a great chance to make contacts from these two institutions, have some intellectual stimulation and network with conference participants. You can even adjourn to the bar afterwards to continue discussions!. You can either register for the Conference and this event or for the event by itself at http://www.ukpharmsci.org/register/default.asp.
SME showcase at APS Pharm Sci Conference 2014:
WEDNESDAY, 2 JULY 2014
Tuesday 9th September from 12.35- 13:30 . The SME Showcase at APS Pharm Sci has become an annual ‘go to’ event for SMEs who want to get their ideas, products and services recognised.. Martino Picardo This year we are fortunate to have Martino Picardo (CEO of the Stevenage Bioscience Catalyst) as our plenary speaker at the session. He, fellow SBC members and session attendees will be available to offer advice and provide contacts. Who knows this might provide the launch pad for your company!. The SME Showcase session is a tangible example of how the Conference theme ‘Working together for Patients’ can be translated into reality.. If you would like to present at the Showcase please contact mailto:dawson@bionetonline.com or maureen.coleman@medinnovate.com with a short abstract (250 words) of your intended presentation..
 
Follow us
 
Upcoming Events
APS PharmSci 2014
8 - 10 September 2014
MIBio 2014 - Stability of biopharmaceuticals- getting the chemistry right
30th September 2014
APS Board Meeting
14 - 15 October 2014
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.